Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Choline | 20 | 2019 | 61 | 6.440 |
Why?
|
| Liver Neoplasms | 15 | 2025 | 224 | 4.370 |
Why?
|
| Carcinoma, Hepatocellular | 15 | 2025 | 163 | 3.840 |
Why?
|
| Positron-Emission Tomography | 14 | 2015 | 93 | 3.030 |
Why?
|
| Radiopharmaceuticals | 10 | 2018 | 62 | 2.300 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2017 | 245 | 2.270 |
Why?
|
| Prostatic Neoplasms | 12 | 2015 | 1092 | 1.750 |
Why?
|
| Prostate-Specific Antigen | 3 | 2016 | 147 | 1.040 |
Why?
|
| Fluorine Radioisotopes | 7 | 2018 | 12 | 0.950 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2015 | 3 | 0.930 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2015 | 3 | 0.930 |
Why?
|
| Aged | 24 | 2025 | 8214 | 0.800 |
Why?
|
| Liver Transplantation | 2 | 2023 | 37 | 0.790 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 375 | 0.680 |
Why?
|
| Radium | 2 | 2017 | 3 | 0.670 |
Why?
|
| Aged, 80 and over | 14 | 2017 | 2853 | 0.670 |
Why?
|
| Research Design | 1 | 2023 | 385 | 0.650 |
Why?
|
| Middle Aged | 25 | 2025 | 12222 | 0.640 |
Why?
|
| Liver | 3 | 2019 | 511 | 0.640 |
Why?
|
| Male | 34 | 2025 | 23409 | 0.640 |
Why?
|
| Humans | 41 | 2025 | 43102 | 0.590 |
Why?
|
| Whole Body Imaging | 3 | 2016 | 25 | 0.590 |
Why?
|
| Phospholipids | 1 | 2017 | 70 | 0.500 |
Why?
|
| Survival Analysis | 5 | 2023 | 368 | 0.490 |
Why?
|
| Tomography, Emission-Computed | 2 | 2007 | 13 | 0.480 |
Why?
|
| Brain Neoplasms | 3 | 2007 | 140 | 0.480 |
Why?
|
| Neoplasms | 2 | 2023 | 1377 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 154 | 0.430 |
Why?
|
| Tumor Burden | 4 | 2016 | 84 | 0.430 |
Why?
|
| Choline Kinase | 1 | 2012 | 2 | 0.390 |
Why?
|
| Hexokinase | 1 | 2012 | 10 | 0.380 |
Why?
|
| Propensity Score | 2 | 2023 | 59 | 0.370 |
Why?
|
| Prospective Studies | 4 | 2021 | 1600 | 0.360 |
Why?
|
| Retrospective Studies | 7 | 2025 | 2544 | 0.360 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 92 | 0.360 |
Why?
|
| Genetic Markers | 1 | 2012 | 150 | 0.350 |
Why?
|
| Splenosis | 1 | 2010 | 2 | 0.340 |
Why?
|
| Pheochromocytoma | 1 | 2010 | 12 | 0.340 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2010 | 20 | 0.330 |
Why?
|
| Liver Cirrhosis | 3 | 2020 | 67 | 0.320 |
Why?
|
| Spleen | 1 | 2010 | 204 | 0.320 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 14 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 220 | 0.310 |
Why?
|
| Female | 18 | 2025 | 24698 | 0.300 |
Why?
|
| Hormones | 1 | 2009 | 55 | 0.300 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 611 | 0.290 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2012 | 17 | 0.290 |
Why?
|
| Disease Progression | 3 | 2017 | 667 | 0.290 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2010 | 301 | 0.270 |
Why?
|
| Hawaii | 5 | 2025 | 2011 | 0.270 |
Why?
|
| Hepatitis B, Chronic | 2 | 2020 | 16 | 0.260 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 1081 | 0.250 |
Why?
|
| Hepatitis | 2 | 2016 | 11 | 0.240 |
Why?
|
| Neoplasm Metastasis | 3 | 2017 | 237 | 0.240 |
Why?
|
| DNA Methylation | 3 | 2016 | 403 | 0.240 |
Why?
|
| Image Enhancement | 1 | 2006 | 37 | 0.240 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2006 | 58 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 587 | 0.230 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 374 | 0.220 |
Why?
|
| Hospitals, Community | 1 | 2004 | 13 | 0.220 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 638 | 0.210 |
Why?
|
| Radionuclide Imaging | 2 | 2015 | 29 | 0.200 |
Why?
|
| Hepatectomy | 1 | 2023 | 8 | 0.200 |
Why?
|
| Incidence | 2 | 2025 | 1078 | 0.200 |
Why?
|
| Prognosis | 3 | 2020 | 861 | 0.200 |
Why?
|
| Glioblastoma | 1 | 2004 | 74 | 0.200 |
Why?
|
| Sample Size | 1 | 2023 | 28 | 0.190 |
Why?
|
| Adult | 10 | 2020 | 13872 | 0.190 |
Why?
|
| Risk Factors | 4 | 2025 | 3994 | 0.180 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 4 | 0.180 |
Why?
|
| Hepatitis B virus | 2 | 2018 | 18 | 0.170 |
Why?
|
| Treatment Outcome | 2 | 2017 | 1604 | 0.160 |
Why?
|
| Hepacivirus | 2 | 2018 | 74 | 0.160 |
Why?
|
| ROC Curve | 3 | 2018 | 159 | 0.160 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2019 | 6 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 495 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 124 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 1723 | 0.140 |
Why?
|
| Neutrophils | 1 | 2019 | 145 | 0.140 |
Why?
|
| Radioisotopes | 1 | 2017 | 17 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 518 | 0.130 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 87 | 0.130 |
Why?
|
| Tissue Extracts | 1 | 2016 | 10 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 3 | 2016 | 526 | 0.120 |
Why?
|
| Androgen Antagonists | 1 | 2016 | 29 | 0.120 |
Why?
|
| Taurochenodeoxycholic Acid | 1 | 2015 | 1 | 0.120 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2015 | 3 | 0.120 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 30 | 0.120 |
Why?
|
| Cholestasis | 1 | 2015 | 12 | 0.120 |
Why?
|
| Biliary Atresia | 1 | 2015 | 7 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 173 | 0.120 |
Why?
|
| Bile Acids and Salts | 1 | 2015 | 37 | 0.120 |
Why?
|
| Beta Particles | 1 | 2015 | 2 | 0.120 |
Why?
|
| Femur Head | 1 | 2015 | 3 | 0.120 |
Why?
|
| Alpha Particles | 1 | 2015 | 4 | 0.110 |
Why?
|
| Urinary Bladder | 1 | 2015 | 30 | 0.110 |
Why?
|
| Rectum | 1 | 2015 | 27 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 704 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2018 | 549 | 0.110 |
Why?
|
| Penis | 1 | 2015 | 90 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2016 | 1285 | 0.110 |
Why?
|
| Time Factors | 2 | 2012 | 1857 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2015 | 259 | 0.100 |
Why?
|
| Prostate | 1 | 2015 | 155 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 44 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 706 | 0.100 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 80 | 0.090 |
Why?
|
| Cholangiocarcinoma | 1 | 2012 | 7 | 0.090 |
Why?
|
| Digestive System Neoplasms | 1 | 2012 | 4 | 0.090 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2012 | 10 | 0.090 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2012 | 27 | 0.090 |
Why?
|
| SEER Program | 1 | 2012 | 164 | 0.090 |
Why?
|
| Electrophoresis, Microchip | 1 | 2012 | 21 | 0.090 |
Why?
|
| Recurrence | 1 | 2012 | 152 | 0.090 |
Why?
|
| Taxoids | 1 | 2012 | 50 | 0.090 |
Why?
|
| Splenectomy | 1 | 2010 | 9 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 440 | 0.080 |
Why?
|
| Phosphorylcholine | 1 | 2010 | 8 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 575 | 0.080 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2010 | 5 | 0.080 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2010 | 74 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2010 | 51 | 0.080 |
Why?
|
| Gene Expression | 1 | 2012 | 701 | 0.080 |
Why?
|
| alpha-Fetoproteins | 2 | 2020 | 32 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2012 | 760 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 49 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2010 | 172 | 0.070 |
Why?
|
| False Negative Reactions | 1 | 2008 | 10 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 59 | 0.070 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2007 | 17 | 0.070 |
Why?
|
| Cyclobutanes | 1 | 2007 | 3 | 0.070 |
Why?
|
| Carboxylic Acids | 1 | 2007 | 15 | 0.070 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 66 | 0.070 |
Why?
|
| Prostatectomy | 1 | 2008 | 70 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1019 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2018 | 95 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 590 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2007 | 140 | 0.060 |
Why?
|
| Retroperitoneal Space | 1 | 2005 | 2 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2020 | 1759 | 0.050 |
Why?
|
| Benchmarking | 1 | 2004 | 32 | 0.050 |
Why?
|
| Demyelinating Diseases | 1 | 2004 | 14 | 0.050 |
Why?
|
| Genetic Loci | 2 | 2016 | 104 | 0.050 |
Why?
|
| Genome, Human | 2 | 2016 | 144 | 0.050 |
Why?
|
| Age Distribution | 1 | 2004 | 249 | 0.050 |
Why?
|
| Demography | 1 | 2004 | 195 | 0.050 |
Why?
|
| Hypertension | 1 | 2010 | 835 | 0.050 |
Why?
|
| Gene Regulatory Networks | 2 | 2016 | 149 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2676 | 0.050 |
Why?
|
| Rats | 1 | 2010 | 3735 | 0.050 |
Why?
|
| Biopsy | 1 | 2020 | 177 | 0.040 |
Why?
|
| Early Detection of Cancer | 2 | 2017 | 449 | 0.040 |
Why?
|
| China | 1 | 2020 | 229 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 5080 | 0.040 |
Why?
|
| Ileum | 1 | 2019 | 20 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2019 | 36 | 0.040 |
Why?
|
| Animals | 2 | 2019 | 16992 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 224 | 0.030 |
Why?
|
| Adolescent | 2 | 2010 | 6081 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 587 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2019 | 321 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 48 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2017 | 135 | 0.030 |
Why?
|
| Internet | 1 | 2018 | 236 | 0.030 |
Why?
|
| Brain | 1 | 2004 | 1472 | 0.030 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2015 | 9 | 0.030 |
Why?
|
| Cholangiography | 1 | 2015 | 4 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 16 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2017 | 246 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 27 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 1410 | 0.030 |
Why?
|
| Metabolome | 1 | 2015 | 51 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 82 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 712 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1154 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 1869 | 0.030 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2013 | 3 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2013 | 13 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 925 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2013 | 64 | 0.020 |
Why?
|
| CpG Islands | 1 | 2013 | 109 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 972 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 1175 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2012 | 74 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 515 | 0.020 |
Why?
|
| Smoking | 1 | 2017 | 1024 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1070 | 0.020 |
Why?
|
| Causality | 1 | 2010 | 45 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2010 | 57 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2010 | 134 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1009 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2010 | 1546 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 1612 | 0.010 |
Why?
|
| Child | 1 | 2010 | 3443 | 0.010 |
Why?
|